↓ Skip to main content

Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review

Overview of attention for article published in BMC Infectious Diseases, April 2012
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (96th percentile)

Mentioned by

blogs
3 blogs
policy
1 policy source
twitter
6 X users
patent
4 patents

Citations

dimensions_citation
219 Dimensions

Readers on

mendeley
333 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review
Published in
BMC Infectious Diseases, April 2012
DOI 10.1186/1471-2334-12-103
Pubmed ID
Authors

Stephen D Lawn

Abstract

Detection of Mycobacterium tuberculosis antigens in urine is attractive as a potential means of diagnosing tuberculosis (TB) regardless of the anatomical site of disease. The most promising candidate antigen is the cell wall lipopolysaccharide antigen lipoarabinomannan (LAM), which has been used to develop commercially available enzyme-linked immunosorbent assays. Although highly variable diagnostic accuracy has been observed in different clinical populations, it is now clear that this assay has useful sensitivity for diagnosis of HIV-associated TB in patients with advanced immunodeficiency and low CD4 cell counts. Thus, this assay is particularly useful when selectively used among patients enrolling in antiretroviral treatment services or in HIV-infected patients requiring admission to hospital medical wards. These are the very patients who have the highest mortality risk and who stand to gain the most from rapid diagnosis, permitting immediate initiation of TB treatment. A recently developed low-cost, lateral-flow (urine 'dip-stick') format of the assay provides a result within 30 minutes and is potentially a major step forward as it can be used at the point-of-care, making the possibility of immediate diagnosis and treatment a reality. This paper discusses the likely utility of this point-of-care assay and how it might best be used in combination with other diagnostic assays for TB. The many further research studies that are needed on this assay are described. Consideration is particularly given to potential reasons for the variable specificity observed in existing field evaluations of LAM ELISAs. Whether this might be related to the assay itself or to the challenges associated with study design is discussed.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 333 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
South Africa 3 <1%
United Kingdom 2 <1%
United States 2 <1%
India 1 <1%
Denmark 1 <1%
Brazil 1 <1%
Unknown 323 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 66 20%
Student > Ph. D. Student 55 17%
Student > Master 52 16%
Student > Bachelor 27 8%
Student > Postgraduate 19 6%
Other 54 16%
Unknown 60 18%
Readers by discipline Count As %
Medicine and Dentistry 113 34%
Agricultural and Biological Sciences 34 10%
Biochemistry, Genetics and Molecular Biology 25 8%
Engineering 18 5%
Immunology and Microbiology 17 5%
Other 51 15%
Unknown 75 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2022.
All research outputs
#1,023,431
of 23,221,875 outputs
Outputs from BMC Infectious Diseases
#235
of 7,785 outputs
Outputs of similar age
#5,636
of 164,465 outputs
Outputs of similar age from BMC Infectious Diseases
#3
of 97 outputs
Altmetric has tracked 23,221,875 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,785 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.3. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 164,465 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.